Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 4, 2020- Recurrent irregular heartbeat--also known as atrial fibrillation--impacts more than 16 million people globally- Trial supports Abbott's focus on being the best partner for electrophysiologists treating people living with atrial fibrillation- Jul 23, 2020- Apple‡ smartphone-compatible digital health tool fits within the company's broader NeuroSphere™ Digital Care connected care management platform, which is designed to optimize care for chronic pain and movement disorders- NeuroSphere Digital Care offers flexible virtual care options as the COVID-19 global pandemic impacts how healthcare is administered- Approval of the Patient Controller app is the latest launch under the NeuroSphere Digital Care(1) platform
- Jul 16, 2020- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales- Growth rates in business areas initially most impacted by COVID-19 improved significantly over the course of the second quarter- Abbott continues to strengthen its portfolio with several recent regulatory approvals, including FreeStyle Libre 2, TriClip and Gallant heart devices
- Jul 6, 2020- Next-generation Gallant™ implantable cardioverter defibrillator family of devices offers Bluetooth® capability for a more meaningful connection between patients and their doctors- Gallant ICD and CRT-D devices feature a patient-preferred design without compromising on battery longevity and compatibility with magnetic resonance imaging (MRI)
- Jun 29, 2020- Companies partner to integrate Abbott's FreeStyle Libre continuous glucose monitoring technology with Tandem's insulin delivery products to provide options to simplify and tailor diabetes management
- Jun 26, 2020-- Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision-- Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack of awareness-- OCT is a high-resolution, infrared light-based imaging technique that provides unparalleled accuracy for physicians during stent implantation
- Jun 25, 2020- New data reinforce Abbott's leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies- Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott's innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings
Jun 15, 2020- FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning- Now for children (ages 4 and older) and adults with diabetes, this latest technology is the first and only iCGM that sustains performance for up to 14 days, providing trends, insights and actionable data- FreeStyle Libre 2 system includes a self-applied sensor (the size of two-stacked quarters) that is easiest glucose sensor to apply[1] and worn on the back of the upper arm, eliminating the need for painful fingersticks to test glucose levels[2]- FreeStyle Libre portfolio has been extensively studied with the most real-world users, delivering proven health outcomes[3]- FreeStyle Libre 2 system offers enhanced features at the same affordable price as FreeStyle Libre 14 day system, which is a third of the cost of other CGMs[4]- Jun 13, 2020- Real-world data(1) presented at the American Diabetes Association 80th Scientific Sessions suggest people with type 2 diabetes can achieve similar outcomes to adding insulin therapy for both long-acting insulin or non-insulin users- A separate late-breaking trial(2) demonstrates FreeStyle Libre portfolio use is associated with significant reductions of acute diabetes events and hospitalizations for a similar population
- May 21, 2020- Urgent care clinic study shows ID NOW test performance of ≥94.7% positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) compared to lab-based PCR reference tests- The Everett Clinic study shows 91.3% positive agreement and 100% negative agreement- Ongoing study of hospitalized and nursing home patients tested with late symptom onset shows ≥83.3% positive agreement and ≥96.5% negative agreement- Abbott's studies suggest ID NOW performs best in patients tested earlier post symptom onset- ID NOW delivers results in minutes rather than days and is helping reduce the spread of infection by detecting more positive patients faster than would otherwise be the case
- May 21, 2020- Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing- European-made blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR, as well as its Alinity™ i laboratory instruments- 800,000 Abbott tests have already been delivered to NHS laboratories across the UK- Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started
- May 12, 2020Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System- Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March- The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours- Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization- This is Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
- May 11, 2020- Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began- Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million in June- Abbott expects to submit for CE Mark for its Alinity i SARS-CoV-2 IgG test this week and will initiate global shipments immediately- This is Abbott's fourth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
- May 8, 2020- Researchers found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began- More than 10 million ARCHITECT antibody tests already have been shipped to hospitals and labs around the world
Apr 27, 2020-- New authorization from Health Canada allows FreeStyle Libre system to be used by frontline healthcare workers in hospitals to remotely monitor patients' glucose status to minimize exposure during COVID-19 and preserve use of personal protective equipment (PPE)-- Abbott will donate 3,000 FreeStyle Libre sensors to Canadian hospitals in need to help accelerate access to technology- Apr 16, 2020- First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent- Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)
Apr 15, 2020- This adds to Abbott's previously announced COVID-19 molecular tests: the m2000™ lab-based test and ID NOW™ rapid point-of-care test- New antibody test will run on Abbott's ARCHITECT® i1000SR and i2000SR laboratory instruments and will expand to its new Alinity™ i system- Abbott begins shipping tomorrow and intends to distribute 4 million tests in April, ramping to 20 million in the U.S. per month in June and beyond- Apr 9, 2020- CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition- New system offers a proven safe and effective minimally invasive non-surgical solution- The TriClip System leverages Abbott's proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy